Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$104.09
+2.4%
$91.76
$18.08
$107.99
$5.55B1.2922,196 shs887,300 shs
Erasca, Inc. stock logo
ERAS
Erasca
$17.72
-2.4%
$15.90
$1.33
$24.28
$5.65B0.664.64 million shs4.20 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$36.95
+1.6%
$32.59
$25.58
$60.08
$1.48B0.46260,114 shs192,133 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$85.47
-3.5%
$83.72
$23.30
$105.47
$5.51B2.111.28 million shs1.46 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-2.76%-3.89%+6.57%+21.69%+356.06%
Erasca, Inc. stock logo
ERAS
Erasca
-3.76%-6.30%+13.32%+99.34%+968.24%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+3.21%+7.41%+14.77%-30.72%+25.76%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+2.32%-7.63%-11.31%+56.17%+142.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$104.09
+2.4%
$91.76
$18.08
$107.99
$5.55B1.2922,196 shs887,300 shs
Erasca, Inc. stock logo
ERAS
Erasca
$17.72
-2.4%
$15.90
$1.33
$24.28
$5.65B0.664.64 million shs4.20 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$36.95
+1.6%
$32.59
$25.58
$60.08
$1.48B0.46260,114 shs192,133 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$85.47
-3.5%
$83.72
$23.30
$105.47
$5.51B2.111.28 million shs1.46 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-2.76%-3.89%+6.57%+21.69%+356.06%
Erasca, Inc. stock logo
ERAS
Erasca
-3.76%-6.30%+13.32%+99.34%+968.24%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+3.21%+7.41%+14.77%-30.72%+25.76%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+2.32%-7.63%-11.31%+56.17%+142.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
2.93
Moderate Buy$117.8213.19% Upside
Erasca, Inc. stock logo
ERAS
Erasca
2.64
Moderate Buy$21.6422.10% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.00
Hold$42.5015.02% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$90.305.65% Upside

Current Analyst Ratings Breakdown

Latest PAHC, ERAS, DNTH, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/20/2026
Erasca, Inc. stock logo
ERAS
Erasca
Boost Price TargetEqual Weight$12.00 ➝ $21.00
7/17/2026
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
Reiterated RatingSell (D-)
7/16/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Set Price Target$110.00
7/14/2026
Erasca, Inc. stock logo
ERAS
Erasca
Reiterated RatingBuy
7/14/2026
Erasca, Inc. stock logo
ERAS
Erasca
Set Price Target$24.00
7/14/2026
Erasca, Inc. stock logo
ERAS
Erasca
Set Price Target$20.00
7/14/2026
Erasca, Inc. stock logo
ERAS
Erasca
Reiterated RatingBuy
7/14/2026
Erasca, Inc. stock logo
ERAS
Erasca
Boost Price TargetNeutral$16.00 ➝ $18.00
7/14/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$90.00 ➝ $120.00
7/6/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
DowngradeOutperformIn-Line$102.00
6/29/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$60.00 ➝ $107.00
(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
$2.04M2,789.51N/AN/A$11.41 per share9.12
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/A$1.05 per shareN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.30B1.16$3.32 per share11.12$7.05 per share5.24
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M14.13N/AN/A$7.84 per share10.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$162.34M-$4.13N/AN/AN/A-12,998.50%-27.30%-25.91%8/6/2026 (Estimated)
Erasca, Inc. stock logo
ERAS
Erasca
-$124.55M-$0.93N/AN/AN/AN/A-35.31%-29.49%8/11/2026 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$2.3315.8611.100.516.35%37.14%8.57%8/26/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%8/3/2026 (Estimated)

Latest PAHC, ERAS, DNTH, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/26/2026Q4 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.72N/AN/AN/A$381.18 millionN/A
8/11/2026Q2 2026
Erasca, Inc. stock logo
ERAS
Erasca
-$0.12N/AN/AN/AN/AN/A
8/6/2026Q2 2026
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$0.93N/AN/AN/A$0.30 millionN/A
8/3/2026Q3 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.50N/AN/AN/A$114.55 millionN/A
5/11/2026Q1 2026
Erasca, Inc. stock logo
ERAS
Erasca
-$0.1150-$0.60-$0.4850-$0.60N/AN/A
5/6/2026Q3 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.72$0.76+$0.04$0.59$367.02 million$383.54 million
5/5/2026Q1 2026
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
-$1.0719-$0.85+$0.2219-$0.85$0.40 million$0.46 million
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
N/AN/AN/AN/AN/A
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.30%N/A20.60%N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A

Latest PAHC, ERAS, DNTH, and TWST Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.32%9/2/20269/2/20269/23/2026
5/5/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.51%6/3/20266/3/20266/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
N/A
29.25
29.25
Erasca, Inc. stock logo
ERAS
Erasca
N/A
9.52
9.52
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.97
3.17
1.26
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42

Institutional Ownership

CompanyInstitutional Ownership
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
47.53%
Erasca, Inc. stock logo
ERAS
Erasca
67.78%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
3.02%
Erasca, Inc. stock logo
ERAS
Erasca
14.20%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.13%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dianthus Therapeutics, Inc. stock logo
DNTH
Dianthus Therapeutics
8054.67 million53.02 millionOptionable
Erasca, Inc. stock logo
ERAS
Erasca
120310.98 million266.83 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.56 million20.23 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dianthus Therapeutics stock logo

Dianthus Therapeutics NASDAQ:DNTH

$104.09 +2.48 (+2.44%)
Closing price 04:00 PM Eastern
Extended Trading
$104.50 +0.41 (+0.39%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Erasca stock logo

Erasca NASDAQ:ERAS

$17.72 -0.44 (-2.42%)
Closing price 04:00 PM Eastern
Extended Trading
$17.50 -0.22 (-1.24%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$36.95 +0.58 (+1.59%)
Closing price 04:00 PM Eastern
Extended Trading
$36.34 -0.61 (-1.65%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$85.47 -3.08 (-3.48%)
Closing price 04:00 PM Eastern
Extended Trading
$84.67 -0.80 (-0.94%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.